Respirology Search
Respirology Respirology
pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Treatment Guideline Chart
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Pulmonary Arterial Hypertension References

  1. Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1)(Suppl 1):63S-71S. doi: 10.1378/chest.126.1_suppl.63S. PMID: 15249495
  2. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1)(Suppl 1):35S-62S. doi: 10.1378/chest.126.1_suppl.35S. PMID: 15249494
  3. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1)(Suppl Suppl):14S-34S. doi: 10.1378/chest.126.1_suppl.14S. PMID: 15249493
  4. Galiè N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun;43(12)(Suppl S):81S-88S. PMID: 15194183
  5. Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001 May;63(9):1789-1798. http://www.aafp.org/. PMID: 11352291
  6. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr;53(17):1573-1619. PMID: 19389575
  7. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct;30(20):2493-2537. doi: 10.1093/eurheartj/ehp297. PMID: 19713419
  8. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun;43(Suppl 12):5S-12S. doi: 10.1016/j.jacc.2004.02.037. PMID: 15194173
  9. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec;25(24):2243-2278. doi: 10.1016/j.ehj.2004.09.014. PMID: 15589643
  10. Channick RN, Rubin LJ. Pulmonary vasculitis and pulmonary hypertension. In: Mason RJ, Murray JF, Broaddus VC, et al. eds. Murray and Nadel’s Textbook of Respiratory Medicine. 4th ed. Philadelphia: Elsevier Saunders; 2005:1465-1474
  11. MedWormhttp://www.medworm.com/rss/index.php/Cardiology/7/http://www.medworm.com/rss/medicalfeeds/specialities/Cardiology.xml
  12. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  13. MedWormhttp://www.medworm.com/rss/index.php/Respiratory-Medicine/40/http://www.medworm.com/rss/medicalfeeds/specialities/Respiratory-Medicine.xml
  14. Medworm - Pulmonary Hypertensionhttp://www.medworm.com/rss/medicalfeeds/conditions/Pulmonary-Hypertension.xml
  15. McCrory DC, Coeytaux RR, Schmit KM, et al. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Comparative Effectiveness Review No. 117. AHRQ. Publication No. 13-EHC087-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013 Apr. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0056718/pdf/TOC.pdf. Accessed 23 Apr 2014.
  16. Hopkins W, Rubin LJ. Treatment of pulmonary hypertension in adults. UpToDate. http://www.uptodate.com/. Feb 2019.
  17. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec;62(Suppl 25):D60-72. doi: 10.1016/j.jacc.2013.10.031. PMID: 24355643
  18. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec;62(Suppl 25):D34-41. http://content.onlinejacc.org/data/Journals/JAC/929484/10029.pdf. Accessed 17 Jul 2014. PMID: 24355639
  19. US Food and Drug Administration. Press Announcements: FDA Approves Opsumit to treat pulmonary arterial hypertension. US Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm371362.htm. Oct 2013.
  20. Patel T, McKeage K. Macitentan: first global approval. Drugs. 2014 Jan;74(1):127-133. doi: 10.1007/s40265-013-0156-6. PMID: 24297706
  21. Galiè N, Humbert M, Vachiery JL, et al; Authors/Task Force Members. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Accessed 26 Nov 2015. PMID: 26320113
  22. Kamangar N. Secondary pulmonary hypertension treatment & management. eMedicine. http://emedicine.medscape.com/article/303098-treatment. Oct 2015.
  23. McLaughlin VV, Channick R, Chin K, et al. Effect of selexipag on mobidity/mortality in pulmonary arterial hypertension: results of GRIPHON study. J Am Coll Cardiol. 2015 Dec;373(26):2522-2533. doi:10.1016/S0735-1097(15)61538-8. PMID: 26699168
  24. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014 Aug;146(2):449-475. doi: 10.1378/chest.14-0793. PMID: 24937180
  25. Frost A, Badesch D, Giibs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01904-2018. PMID: 30545972
  26. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01889-2018. PMID: 30545971
  27. Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.02148-2018. PMID: 30552088
  28. Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01906-2018. PMID: 30545979
  29. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01887-2018. PMID: 30545970
  30. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019 Mar;155(3):565-586. doi: 10.1016/j.chest.2018.11.030. PMID: 30660783
  31. Rubin LJ, Hopkins W. Classification and prognosis of pulmonary hypertension in adults. UptoDate. http://www.uptodate.com/. Feb 2019.
  32. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan;53(1). doi: 10.1183/13993003.01913-2018. PMID: 30545968
  33. Condon DF, Nickel NP, Anderson R, et al. The 6th world symposium on pulmonary hypertension: what’s old is new. F1000Res. 2019 Jun;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672.
  34. Hirani N, Brunner NW, Kapasi A, et al. Canadian Cardiovascular Society/Canadian Thoracic Society position statement on pulmonary hypertension. Can J Cardiol. 2020 Jul;36(7):977-992. doi: 10.1016/j.cjca.2019.11.041. PMID: 32682511
  35. Hopkins W, Rubin LJ. Treatment and prognosis of pulmonary arterial hypertension in adults (group 1). UpToDate. https://www.uptodate.com. 24 Jan 2020.
  36. Hopkins W, Rubin LJ. Treatment of pulmonary arterial hypertension (group 1) in adults: pulmonary hypertension-specific therapy. UpToDate. https://www.uptodate.com. 20 Aug 2020.
  37. Rubin LJ, Hopkins W. The epidemiology and pathogenesis of pulmonary arterial hypertension. UpToDate. https://www.uptodate.com. 29 Feb 2020.
  38. Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020 Sep;56(3):2000673. doi: 10.1183/13993003.00673-2020. PMID: 32350101
  39. Thomas CA, Anderson RJ, Condon DF, et al. Diagnosis and management of pulmonary hypertension in the modern era: insights from the 6th world symposium. Pulm Ther. 2020 Jun;6(1):9-22. doi: 10.1007/s41030-019-00105-5. PMID: 32048239
Editor's Recommendations
Special Reports
MORE Special Reports arrow
Related Disease News
MORE Disease News arrow